
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2030137/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The mechanisms of action of metformin. Diabetologia, 2017, 60, 1577-1585.	6.3	1,421
2	Activating Mutations in the Gene Encoding the ATP-Sensitive Potassium-Channel Subunit Kir6.2 and Permanent Neonatal Diabetes. New England Journal of Medicine, 2004, 350, 1838-1849.	27.0	1,077
3	Switching from Insulin to Oral Sulfonylureas in Patients with Diabetes Due to Kir6.2 Mutations. New England Journal of Medicine, 2006, 355, 467-477.	27.0	878
4	Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet, The, 2003, 362, 1275-1281.	13.7	526
5	Metformin and the gastrointestinal tract. Diabetologia, 2016, 59, 426-435.	6.3	472
6	Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nature Genetics, 2011, 43, 117-120.	21.4	390
7	Macrosomia and Hyperinsulinaemic Hypoglycaemia in Patients with Heterozygous Mutations in the HNF4A Gene. PLoS Medicine, 2007, 4, e118.	8.4	349
8	New loci associated with birth weight identify genetic links between intrauterine growth and adult height and metabolism. Nature Genetics, 2013, 45, 76-82.	21.4	293
9	Variation in <i>TCF7L2</i> Influences Therapeutic Response to Sulfonylureas. Diabetes, 2007, 56, 2178-2182.	0.6	284
10	Using machine learning approaches for multi-omics data analysis: A review. Biotechnology Advances, 2021, 49, 107739.	11.7	277
11	Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2020, 43, 1617-1635.	8.6	204
12	Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study. Diabetes, 2015, 64, 1786-1793.	0.6	188
13	Relapsing diabetes can result from moderately activating mutations in KCNJ11. Human Molecular Genetics, 2005, 14, 925-934.	2.9	184
14	Systematic Population Screening, Using Biomarkers and Genetic Testing, Identifies 2.5% of the U.K. Pediatric Diabetes Population With Monogenic Diabetes. Diabetes Care, 2016, 39, 1879-1888.	8.6	172
15	Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Nature Genetics, 2016, 48, 1055-1059.	21.4	165
16	Reduced-Function <i>SLC22A1</i> Polymorphisms Encoding Organic Cation Transporter 1 and Glycemic Response to Metformin: A GoDARTS Study. Diabetes, 2009, 58, 1434-1439.	0.6	153
17	Type 2 diabetes: a multifaceted disease. Diabetologia, 2019, 62, 1107-1112.	6.3	129
18	Genetic Evidence for a Link Between Favorable Adiposity and Lower Risk of Type 2 Diabetes, Hypertension, and Heart Disease. Diabetes, 2016, 65, 2448-2460.	0.6	122

#	Article	IF	CITATIONS
19	Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study. Lancet Diabetes and Endocrinology,the, 2018, 6, 637-646.	11.4	120
20	Contrasting Diabetes Phenotypes Associated With Hepatocyte Nuclear Factor-1Â and -1Â Mutations. Diabetes Care, 2004, 27, 1102-1107.	8.6	114
21	Novel subgroups of type 2 diabetes and their association with microvascular outcomes in an Asian Indian population: a data-driven cluster analysis: the INSPIRED study. BMJ Open Diabetes Research and Care, 2020, 8, e001506.	2.8	112
22	Population-Based Assessment of a Biomarker-Based Screening Pathway to Aid Diagnosis of Monogenic Diabetes in Young-Onset Patients. Diabetes Care, 2017, 40, 1017-1025.	8.6	111
23	Most People With Long-Duration Type 1 Diabetes in a Large Population-Based Study Are Insulin Microsecretors. Diabetes Care, 2015, 38, 323-328.	8.6	104
24	A Genome-Wide Association Study of IVGTT-Based Measures of First-Phase Insulin Secretion Refines the Underlying Physiology of Type 2 Diabetes Variants. Diabetes, 2017, 66, 2296-2309.	0.6	102
25	Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2020, 63, 1671-1693.	6.3	102
26	Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial. Diabetes Care, 2020, 43, 1356-1359.	8.6	102
27	Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis. Lancet Diabetes and Endocrinology,the, 2014, 2, 481-487.	11.4	101
28	Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. Diabetes Care, 2018, 41, 1844-1853.	8.6	91
29	Visit-to-Visit HbA1c Variability Is Associated With Cardiovascular Disease and Microvascular Complications in Patients With Newly Diagnosed Type 2 Diabetes. Diabetes Care, 2020, 43, 426-432.	8.6	85
30	C-Peptide Decline in Type 1 Diabetes Has Two Phases: An Initial Exponential Fall and a Subsequent Stable Phase. Diabetes Care, 2018, 41, 1486-1492.	8.6	81
31	Adherence to Oral Glucose-Lowering Therapies and Associations With 1-Year HbA1c: A Retrospective Cohort Analysis in a Large Primary Care Database. Diabetes Care, 2016, 39, 258-263.	8.6	79
32	Genome-Wide and Abdominal MRI Data Provide Evidence That a Genetically Determined Favorable Adiposity Phenotype Is Characterized by Lower Ectopic Liver Fat and Lower Risk of Type 2 Diabetes, Heart Disease, and Hypertension. Diabetes, 2019, 68, 207-219.	0.6	72
33	Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. Diabetes Care, 2018, 41, 705-712.	8.6	67
34	A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin. Diabetologia, 2018, 61, 2520-2527.	6.3	65
35	Monogenic Diabetes: From Genetic Insights to Population-Based Precision in Care. Reflections From a <i>Diabetes Care</i> Editors' Expert Forum. Diabetes Care, 2020, 43, 3117-3128.	8.6	65
36	Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010–2017. Diabetes, Obesity and Metabolism, 2019, 21, 1576-1584.	4.4	64

EWAN R PEARSON

#	Article	IF	CITATIONS
37	Clinical and Genetic Determinants of Progression of Type 2 Diabetes: A DIRECT Study. Diabetes Care, 2014, 37, 718-724.	8.6	59
38	Cohort Profile: Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS). International Journal of Epidemiology, 2018, 47, 380-381j.	1.9	59
39	The Relationship between AKI and CKD in Patients with Type 2 Diabetes: An Observational Cohort Study. Journal of the American Society of Nephrology: JASN, 2021, 32, 138-150.	6.1	56
40	Formalising recall by genotype as an efficient approach to detailed phenotyping and causal inference. Nature Communications, 2018, 9, 711.	12.8	54
41	<i>CYP2C8</i> and <i>SLCO1B1</i> Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes. Diabetes Care, 2016, 39, 1902-1908.	8.6	52
42	Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. Cardiovascular Diabetology, 2016, 15, 97.	6.8	49
43	Acute kidney injury, plasma lactate concentrations and lactic acidosis in metformin users: <scp>A GoDarts</scp> study. Diabetes, Obesity and Metabolism, 2017, 19, 1579-1586.	4.4	49
44	Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 18–50 years. BMJ Open, 2019, 9, e031586.	1.9	49
45	Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium. Diabetologia, 2014, 57, 1132-1142.	6.3	48
46	Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes. Nature Medicine, 2022, 28, 982-988.	30.7	48
47	Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery. Nature Reviews Endocrinology, 2016, 12, 337-346.	9.6	47
48	Sustained influence of metformin therapy on circulating glucagonâ€like peptideâ€1 levels in individuals with and without type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 356-363.	4.4	47
49	Performance of Cardiovascular Disease Risk Scores in People Diagnosed With Type 2 Diabetes: External Validation Using Data From the National Scottish Diabetes Register. Diabetes Care, 2018, 41, 2010-2018.	8.6	47
50	Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts. PLoS Medicine, 2020, 17, e1003149.	8.4	47
51	Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care, 2020, 43, 1948-1957.	8.6	45
52	Replication and cross-validation of type 2 diabetes subtypes based on clinical variables: an IMI-RHAPSODY study. Diabetologia, 2021, 64, 1982-1989.	6.3	44
53	Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by <i>SLC29A4</i>) and Organic Cation Transporter 1 (OCT1) (Encoded by <i>SLC22A1</i>) and Gastrointestinal Intolerance to Metformin in Type 2 Diabetes: An IMI DIRECT Study. Diabetes Care, 2019, 42, 1027-1033.	8.6	43
54	Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation BMI Open Diabetes Research and Care, 2020, 8, e001238	2.8	43

#	Article	IF	CITATIONS
55	Effect of Serotonin Transporter 5-HTTLPR Polymorphism on Gastrointestinal Intolerance to Metformin: A GoDARTS Study. Diabetes Care, 2016, 39, 1896-1901.	8.6	41
56	A common missense variant of LILRB5 is associated with statin intolerance and myalgia. European Heart Journal, 2017, 38, 3569-3575.	2.2	41
57	Quantifying the extent to which index event biases influence large genetic association studies. Human Molecular Genetics, 2017, 26, ddw433.	2.9	40
58	Rates of glycaemic deterioration in a real-world population with type 2 diabetes. Diabetologia, 2018, 61, 607-615.	6.3	40
59	Four groups of type 2 diabetes contribute to the etiological and clinical heterogeneity in newly diagnosed individuals: An IMI DIRECT study. Cell Reports Medicine, 2022, 3, 100477.	6.5	39
60	A Type 1 Diabetes Genetic Risk Score Can Identify Patients With GAD65 Autoantibody–Positive Type 2 Diabetes Who Rapidly Progress to Insulin Therapy. Diabetes Care, 2019, 42, 208-214.	8.6	35
61	Sharing data for future research'engaging participants' views about data governance beyond the original project: a DIRECT Study. Genetics in Medicine, 2019, 21, 1131-1138.	2.4	34
62	Genetic Variants in <i>CPA6</i> and <i>PRPF31</i> Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes. Diabetes, 2018, 67, 1428-1440.	0.6	32
63	Metabolite ratios as potential biomarkers for type 2 diabetes: a DIRECT study. Diabetologia, 2018, 61, 117-129.	6.3	32
64	Young-onset diabetes in Asian Indians is associated with lower measured and genetically determined beta cell function. Diabetologia, 2022, 65, 973-983.	6.3	32
65	Obesity, clinical, and genetic predictors for glycemic progression in Chinese patients with type 2 diabetes: A cohort study using the Hong Kong Diabetes Register and Hong Kong Diabetes Biobank. PLoS Medicine, 2020, 17, e1003209.	8.4	31
66	Elevated circulating follistatin associates with an increased risk of type 2 diabetes. Nature Communications, 2021, 12, 6486.	12.8	31
67	Motivations for data sharing—views of research participants from four European countries: A DIRECT study. European Journal of Human Genetics, 2019, 27, 721-729.	2.8	30
68	Diabetes: Is There a Future for Pharmacogenomics Guided Treatment?. Clinical Pharmacology and Therapeutics, 2019, 106, 329-337.	4.7	29
69	Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study. Diabetes Care, 2020, 43, 2493-2499.	8.6	29
70	Distinct Molecular Signatures of Clinical Clusters in People With Type 2 Diabetes: An IMI-RHAPSODY Study. Diabetes, 2021, 70, 2683-2693.	0.6	26
71	Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c?. PLoS ONE, 2016, 11, e0152428.	2.5	26
72	Defining drug response for stratified medicine. Drug Discovery Today, 2017, 22, 173-179.	6.4	24

#	Article	IF	CITATIONS
73	Interaction between variants in the CYP2C9 and POR genes and the risk of sulfonylureaâ€induced hypoglycaemia: A GoDARTS S tudy. Diabetes, Obesity and Metabolism, 2018, 20, 211-214.	4.4	24
74	Genetic studies of abdominal MRI data identify genes regulating hepcidin as major determinants of liver iron concentration. Journal of Hepatology, 2019, 71, 594-602.	3.7	23
75	Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care, 2021, 44, 2673-2682.	8.6	23
76	Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium. Diabetologia, 2019, 62, 1601-1615.	6.3	22
77	Metformin increases fasting glucose clearance and endogenous glucose production in non-diabetic individuals. Diabetologia, 2020, 63, 444-447.	6.3	22
78	A Polygenic Score for Type 2 Diabetes Risk Is Associated With Both the Acute and Sustained Response to Sulfonylureas. Diabetes, 2021, 70, 293-300.	0.6	22
79	No differences in mortality between users of pancreatic-specific and non-pancreatic-specific sulphonylureas: a cohort analysis. Diabetes, Obesity and Metabolism, 2008, 10, 350-352.	4.4	20
80	Zinc Transporter 8 Autoantibodies (ZnT8A) and a Type 1 Diabetes Genetic Risk Score Can Exclude Individuals With Type 1 Diabetes From Inappropriate Genetic Testing for Monogenic Diabetes. Diabetes Care, 2019, 42, e16-e17.	8.6	19
81	Zinc transport and diabetes risk. Nature Genetics, 2014, 46, 323-324.	21.4	18
82	Profiles of Glucose Metabolism in Different Prediabetes Phenotypes, Classified by Fasting Glycemia, 2-Hour OGTT, Glycated Hemoglobin, and 1-Hour OGTT: An IMI DIRECT Study. Diabetes, 2021, 70, 2092-2106.	0.6	17
83	Improvements in Awareness and Testing Have Led to a Threefold Increase Over 10 Years in the Identification of Monogenic Diabetes in the U.K Diabetes Care, 2022, 45, 642-649.	8.6	17
84	Pharmacogenetics and future strategies in treating hyperglycaemia in diabetes. Frontiers in Bioscience - Landmark, 2009, Volume, 4348.	3.0	16
85	Processes Underlying Glycemic Deterioration in Type 2 Diabetes: An IMI DIRECT Study. Diabetes Care, 2021, 44, 511-518.	8.6	16
86	Association of Genetic Variant at Chromosome 12q23.1 With Neuropathic Pain Susceptibility. JAMA Network Open, 2021, 4, e2136560.	5.9	16
87	A roadmap to achieve pharmacological precision medicine in diabetes. Diabetologia, 2022, 65, 1830-1838.	6.3	16
88	Evaluating associations between the benefits and risks of drug therapy in type 2 diabetes: a joint modeling approach. Clinical Epidemiology, 2018, Volume 10, 1869-1877.	3.0	14
89	Predicting glycated hemoglobin levels in the non-diabetic general population: Development and validation of the DIRECT-DETECT prediction model - a DIRECT study. PLoS ONE, 2017, 12, e0171816.	2.5	13
90	The role of physical activity in metabolic homeostasis before and after the onset of type 2 diabetes: an IMI DIRECT study. Diabetologia, 2020, 63, 744-756.	6.3	12

#	Article	IF	CITATIONS
91	Reflections on the sulphonylurea story: A drug class at risk of extinction or a drug class worth reviving?. Diabetes, Obesity and Metabolism, 2019, 21, 761-771.	4.4	11
92	Prediction of Major Adverse Cardiovascular Events From Retinal, Clinical, and Genomic Data in Individuals With Type 2 Diabetes: A Population Cohort Study. Diabetes Care, 2022, 45, 710-716.	8.6	11
93	Statistical power considerations in genotype-based recall randomized controlled trials. Scientific Reports, 2016, 6, 37307.	3.3	10
94	What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study. BMC Medicine, 2019, 17, 79.	5.5	10
95	Costs and Treatment Pathways for Type 2 Diabetes in the UK: A Mastermind Cohort Study. Diabetes Therapy, 2017, 8, 1031-1045.	2.5	9
96	The Impact of Low-dose Gliclazide on the Incretin Effect and Indices of Beta-cell Function. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2036-2046.	3.6	9
97	Integrative network analysis highlights biological processes underlying GLP-1 stimulated insulin secretion: A DIRECT study. PLoS ONE, 2018, 13, e0189886.	2.5	9
98	Dorothy Hodgkin Lecture 2021: Drugs, genes and diabetes. Diabetic Medicine, 2021, 38, e14726.	2.3	9
99	Pharmacogenetics and target identification in diabetes. Current Opinion in Genetics and Development, 2018, 50, 68-73.	3.3	8
100	Whole blood co-expression modules associate with metabolic traits and type 2 diabetes: an IMI-DIRECT study. Genome Medicine, 2020, 12, 109.	8.2	8
101	Strategies to identify individuals with monogenic diabetes: results of an economic evaluation. BMJ Open, 2020, 10, e034716.	1.9	8
102	Dissecting the Etiology of Type 2 Diabetes in the Pima Indian Population. Diabetes, 2015, 64, 3993-3995.	0.6	7
103	The governance structure for data access in the DIRECT consortium: an innovative medicines initiative (IMI) project. Life Sciences, Society and Policy, 2018, 14, 20.	3.2	7
104	Cohort profile: DOLORisk Dundee: a longitudinal study of chronic neuropathic pain. BMJ Open, 2021, 11, e042887.	1.9	7
105	Post-load glucose subgroups and associated metabolic traits in individuals with type 2 diabetes: An IMI-DIRECT study. PLoS ONE, 2020, 15, e0242360.	2.5	7
106	Quantitative MRI evaluation of whole abdomen adipose tissue volumes in healthy volunteers—validation of technique and implications for clinical studies. British Journal of Radiology, 2018, 91, 20180025.	2.2	6
107	Interaction between Omeprazole and Gliclazide in Relation to CYP2C19 Phenotype. Journal of Personalized Medicine, 2021, 11, 367.	2.5	6
108	CKMGlu83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	5

#	Article	IF	CITATIONS
109	Genome-Wide Association Analysis of Pancreatic Beta-Cell Glucose Sensitivity. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 80-90.	3.6	5
110	Utilizing Large Electronic Medical Record Data Sets to Identify Novel Drug–Gene Interactions for Commonly Used Drugs. Clinical Pharmacology and Therapeutics, 2021, 110, 816-825.	4.7	5
111	Evidence of a Causal Relationship between Serum Thyroid-Stimulating Hormone and Osteoporotic Bone Fractures. European Thyroid Journal, 2021, 10, 439-446.	2.4	5
112	Evidence-based prioritisation and enrichment of genes interacting with metformin in type 2 diabetes. Diabetologia, 2017, 60, 2231-2239.	6.3	4
113	Circulating Tissue Factor-Positive Procoagulant Microparticles in Patients with Type 1 Diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 12, 2819-2828.	2.4	4
114	Genetic Risk of Diverticular Disease Predicts Early Stoppage of Nicorandil. Clinical Pharmacology and Therapeutics, 2020, 108, 1171-1175.	4.7	4
115	The impact of birthweight on subsequent phenotype of type 2 diabetes in later life. Diabetic Medicine, 2022, 39, e14792.	2.3	4
116	The search for predictive metabolic biomarkers for incident T2DM. Nature Reviews Endocrinology, 2018, 14, 444-446.	9.6	3
117	Predicting post one-year durability of glucose-lowering monotherapies in patients with newly-diagnosed type 2 diabetes mellitus – A MASTERMIND precision medicine approach (UKPDS 87). Diabetes Research and Clinical Practice, 2020, 166, 108333.	2.8	3
118	Dietary metabolite profiling brings new insight into the relationship between nutrition and metabolic risk: An IMI DIRECT study. EBioMedicine, 2020, 58, 102932.	6.1	3
119	The role of genetics in fetal programming of adult cardiometabolic disease. Journal of Developmental Origins of Health and Disease, 2022, 13, 292-299.	1.4	3
120	Prescribing Patterns and Response to Antihyperglycemic Agents Among Novel Clusters of Type 2 Diabetes in Asian Indians. Diabetes Technology and Therapeutics, 2022, 24, 190-200.	4.4	3
121	Reducing Clut2 throughout the body does not result in cognitive behaviour differences in aged male mice. BMC Research Notes, 2020, 13, 438.	1.4	2
122	Genomic editing of metformin efficacy-associated genetic variants in SLC47A1 does not alter SLC47A1 expression. Human Molecular Genetics, 2021, , .	2.9	2
123	4th ESPT Conference: pharmacogenomics and personalized medicine– research progress and clinical implementation. Pharmacogenomics, 2019, 20, 1063-1069.	1.3	1
124	In a cohort of individuals with type 2 diabetes using the drug sulfasalazine, HbA 1c lowering is associated with haematological changes. Diabetic Medicine, 2020, 38, e14463.	2.3	1
125	Polymorphism in INSR Locus Modifies Risk of Atrial Fibrillation in Patients on Thyroid Hormone Replacement Therapy. Frontiers in Genetics, 2021, 12, 652878.	2.3	1
126	Precision Medicine in Diabetes. Handbook of Experimental Pharmacology, 2022, , .	1.8	1

#	Article	IF	CITATIONS
127	PS7 - 3. Predicting Glycated Haemoglobin in the Non-Diabetic General Population: a DIRECT Study. Nederlands Tijdschrift Voor Diabetologie, 2013, 11, 154-154.	0.0	0
128	Crossover studies can help the individualisation of care in type 2 diabetes: the MASTERMIND approach. Practical Diabetes, 2016, 33, 115-117.	0.3	0
129	Response to Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SCLT-2i, and CLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948–1957. Diabetes Care, 2020, 43, e202-e203.	8.6	0
130	Genome-Wide Meta-Analysis Identifies the Organic Anion-Transporting Polypeptide Gene <i>SLCO1B1</i> and Statins as Modifiers of Glycemic Response to Sulfonylureas. SSRN Electronic Journal, 0, , .	0.4	0
131	The genetic association of the transcription factor NPAT with glycemic response to metformin involves regulation of fuel selection. PLoS ONE, 2021, 16, e0253533.	2.5	0
132	Response to Comment on Dawed et al. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care 2021;44:2673–2682. Diabetes Care, 2022, 45, e82-e83.	8.6	0
133	Title is missing!. , 2020, 17, e1003149.		0
134	Title is missing!. , 2020, 17, e1003149.		0
135	Title is missing!. , 2020, 17, e1003149.		0
136	Title is missing!. , 2020, 17, e1003149.		0
137	Title is missing!. , 2020, 17, e1003149.		0